Roche Gets Boost From FDA in Bid to Expand Uses for Actemra Roche Gets Boost From FDA in Bid to Expand Uses for Actemra
The U.S. Food and Drug Administration has granted breakthrough status to Roche ' s rheumatoid arthritis medication Actemra (tocilizumab) for giant cell arteritis, the Swiss drugmaker said, a step which could help it broaden applications for the medicine.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
More News: Actemra | Allergy | Allergy & Immunology | Arthritis | Food and Drug Administration (FDA) | Health | Rheumatoid Arthritis | Rheumatology